This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

9 Biotech Penny Stocks to Buy

6. Luna Innovations (LUNA)

Market Cap: $24.14 million

Luna Innovations (LUNA - Get Report) is engaged in research, development and commercializing of technologies in two primary areas of focus: test and measurement, sensing, and instrumentation products and health care products. Luna shares have gained an impressive 196.8% since the end of Aug. 2009 despite the dip share prices have taken this summer. Don't count out the long-term earning potential for this Roanoke, Va.-based small-cap.

7. Neuralstem (CUR)

Market Cap: $90.72 million

Neuralstem (CUR - Get Report) is focused on developing and commercializing of treatments for central nervous system disease based on transplanting human neural stem cells and small molecule drugs. The future could be bright as the company continues to work into their clinical trials to treat Lou Gehrig's disease; shares of this Rockland, Md.-based Neuralstem have gone up in value 80% since this time last year.

8. AVI BioPharma (AVII)

Market Cap: $246.311 million

AVI BioPharma (AVII) is a biopharmaceutical company specializing in the discovery and development of ribonucleic acid (RNA) based drugs targeting a range of diseases. AVII shares have been on an impressive climb this summer and shareholders have already enjoyed 54% gains since June. The Washington-based company has also beat earnings estimates during two of the past three quarters and is getting the attention of savvy investors looking to add some stability to their portfolio.

9. DUSA Pharmaceuticals (DUSA)

Market Cap: $55.44 million

DUSA Pharmaceuticals (DUSA) is a vertically integrated dermatology company that is developing and marketing Levulan photodynamic therapy and other products for common skin conditions. With 99% increases in DUSA share value from one year ago, investors who haven't heard of this small-cap stock will likely be taking notice of the high-value and low financial commitment involved in DUSA stock.

As of this writing, Louis Navellier did not own a position in any of the stocks named here.

One of Wall Street's renowned growth investors, Louis Navellier is the editor of four investing newsletters: Emerging Growth (formerly known as MPT Review), Blue Chip Growth, Quantum Growth and Global Growth. His longest-running publication, Emerging Growth, has a track record of beating the market nearly 3 to 1. Navellier is the author of a BusinessWeek bestseller, "The Little Book That Makes You Rich," and the chairman and founder of Navellier & Associates, Inc.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ATHX $1.19 -5.60%
CYCC $0.77 4.00%
CPRX $3.91 -8.22%
CUR $1.78 -11.88%
LUNA $1.04 0.00%

Markets

DOW 17,596.35 -350.33 -1.95%
S&P 500 2,057.64 -43.85 -2.09%
NASDAQ 4,958.4680 -122.0370 -2.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs